Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review

Table 1

Reported cases of malignancies with the use of tofacitinib.

	Reported malignancies (excluding NMSC)	Malignancy crude IR	Malignancy IR/100 py
Rheumatoid arthritis
Curtis et al. [3]	Lung, breast, and gastric lymphoma and T-cell CLL	1.88	0.85
Cohen et al. [4]	Lung disorders, breast disorders, and lymphoma/lymphoproliferative disorders	2.79	0.89
Yamanaka et al. [5]	Gastric, breast, ovarian, colon, lung, fallopian tube, thyroid, esophageal, and lymphoproliferative disorders, acute myeloid leukemia, liposarcoma, and transitional cell carcinoma	3.9	1.2
Psoriatic arthritis
OPAL trials [6–8]	Breast carcinoma, transitional cell carcinoma, and vulvar squamous cell carcinoma	2.8 (OPAL Broaden)	2.8 (OPAL Broaden)
		0.3 (OPAL Balance)	— (OPAL Balance)
Ulcerative colitis
OCTAVE trials + LTE [9, 10]	—	0.48	—
Xie and Ma [11]	Acute myeloid leukemia	—	—

The cancer types mentioned were only reported in OPAL Broaden. In the ongoing OPAL Balance, there was no specification of the cancer types. In the ongoing LTE study (NCT014770612), there was no specification of the cancer types.